Evidence map›Paper›PMID 36855160›Full record

ArticleTrials2023

Trial protocol for a multicenter randomized controlled trial to assess the efficacy and safety of intravenous ketamine for chronic daily headaches: the "KetHead" trial.

Yasmine Hoydonckx, Mandeep Singh, Ian Gilron, James Khan, Samer Narouze, Albert Dahan, Kathryn Curtis, Xingshan Cao, Jamal Kara, Anuj Bhatia

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05306899 (A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05306899 phase3recruitingnot on this map

A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study

TypeinterventionalSponsorUniversity Health Network, TorontoRan2022 to 2027Enrolled56ConditionsChronic Daily HeadacheArmsKetamine, 0.9% Saline
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Glutamate as a Therapeutic Substrate in Migraine.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Yasmine HoydonckxDepartment of Anesthesia and Pain Medicine, University of Toronto, Toronto Western Hospital, McL 2-405, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada. Yasmine.hoydonckx@uhn.ca.ORCID http://orcid.org/0000-0003-0893-8813
Mandeep SinghDepartment of Anesthesia and Pain Medicine, University of Toronto, Toronto Western Hospital, McL 2-405, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada.
Ian GilronDepartments of Anesthesiology & Perioperative Medicine and Biomedical & Molecular Sciences, Centre for Neuroscience Studies, School of Policy Studies, Queens University, Kingston, Canada.
James KhanDepartment of Anesthesia and Pain Medicine, University of Toronto, Sinai Health System, Toronto, Ontario, Canada.
Samer NarouzeDepartment of Anesthesia and Pain Medicine, Western Reserve Hospital, Cuyahoga Falls, OH, USA.
Albert DahanDepartment of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
Kathryn CurtisDepartment of Anesthesia and Pain Medicine, University of Toronto, Toronto Western Hospital, McL 2-405, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada.
Xingshan CaoSunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Jamal KaraDepartment of Anesthesia and Pain Medicine, University of Toronto, Toronto Western Hospital, McL 2-405, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada.
Anuj BhatiaDepartment of Anesthesia and Pain Medicine, University of Toronto, Toronto Western Hospital, McL 2-405, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada.
University of Toronto · CALeiden University Medical Center · NLQueen's University · CASunnybrook Health Science Centre · CAUniversity Health Network · CAWestern Reserve Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic daily headaches (CDH) are common and associated with significant morbidity, poor quality of life, and substantial burden on the healthcare system. CDH tends to be refractory to conventional medical management and/or patients cannot afford expensive treatments. It is stipulated that CDH share a mechanism of central sensitization in the trigeminocervical complex, mediated by activation of the N-methyl-D-aspartate (NMDA) receptors. Ketamine, a non-competitive NMDA antagonist, has been used in the treatment of chronic pain, but its role in CDH has not been completely established. This trial aims to evaluate the effect of high-dose IV ketamine infusions (compared to placebo) on the number of headache days at 28 days post-infusion.

methodsA multicenter, placebo-controlled, randomized controlled trial will be conducted with two parallel groups and blinding of participants and outcome assessors. The study will include 56 adults with a CDH diagnosis as per ICHD-3 criteria. Participants will be randomized (1:1) to either ketamine (1 mg. kg

trial registrationClinicalTrials.gov NCT05306899. Registered on April 1, 2022.

Indexed as

Headache DisordersKetamineAdultHeadacheHumansMulticenter Studies as TopicN-MethylaspartateQuality of LifeRandomized Controlled Trials as TopicKetamineN-MethylaspartateChronic daily headachesKetamineMigraineNMDA receptorPainQuality of life

Identifiers

PMID36855160
PMCPMC9976458
OpenAlexW4322621231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.